Matthew P. Connor

Matthew P. Connor, MD is an Assistant Professor of Clinical Medicine in Hematology-Oncology at the University of Pennsylvania's Penn Medicine, holding hospital privileges at the Hospital of the University of Pennsylvania. He completed medical training at Rosalind Franklin University followed by residency and fellowship at the Hospital of the University of Pennsylvania.

Dr. Connor's research focuses on real-world applications of CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia (ALL), particularly brexucabtagene autoleucel (Brexu-cel). His work with the ROCCA Consortium examines critical dimensions including:

• Social determinants of health impacts on treatment outcomes
• CNS involvement and toxicity predictors using hematotox scores
• Minimal residual disease monitoring via NGS
• Treatment sequencing with tyrosine kinase inhibitors
• Special populations including elderly patients and KMT2A-rearranged cases

His 10 publications in 2024-2025 demonstrate expertise in generating real-world evidence from multicenter collaborations across major U.S. cancer centers. Dr. Connor's clinical practice focuses on medical oncology for adult leukemia patients, with active involvement in advancing CAR-T therapy implementation.